LOAN AGREEMENTGuaranty and Security Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of December 13, 2019 (the “Effective Date”) by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), the Guarantors from time to time party hereto, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
GUARANTY AND SECURITY AGREEMENT Dated as of December 20, 2019 by SAREPTA THERAPEUTICS, INC. (as Borrower), THE GUARANTORS PARTY HERETO, andGuaranty and Security Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, pursuant to the Loan Agreement dated as of December 13, 2019 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Borrower, the Collateral Agent and the other parties thereto, Lenders agrees to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;
STOCK PURCHASE AGREEMENT By and Between Sarepta Therapeutics, Inc. and Roche Finance Ltd Dated December 21, 2019Stock Purchase Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of December 21, 2019, by and between Sarepta Therapeutics, Inc., a Delaware corporation (the “Company”), and Roche Finance Ltd, a Swiss company (the “Purchaser”). The Company and the Purchaser may be referred to herein individually as a “Party” and collectively as the “Parties.”
License, Collaboration, and Option Agreement, and Option Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This License, Collaboration, and Option Agreement (this “Agreement”) is made and entered into as of December 21, 2019 (the “Execution Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”).
